NASDAQ:SVRA Savara (SVRA) Stock Price, News & Analysis $4.42 -0.12 (-2.64%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$4.35▼$4.6450-Day Range$3.96▼$5.0752-Week Range$3.12▼$5.70Volume1.04 million shsAverage Volume1.21 million shsMarket Capitalization$610.80 millionP/E RatioN/ADividend YieldN/APrice Target$11.17 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Savara alerts: Email Address Savara MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside152.6% Upside$11.17 Price TargetShort InterestBearish9.57% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.59Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.44) to ($0.42) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.46 out of 5 starsMedical Sector663rd out of 910 stocksPharmaceutical Preparations Industry305th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingSavara has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSavara has only been the subject of 4 research reports in the past 90 days.Read more about Savara's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.57% of the float of Savara has been sold short.Short Interest Ratio / Days to CoverSavara has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in Savara has recently increased by 9.35%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSavara does not currently pay a dividend.Dividend GrowthSavara does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SVRA. Previous Next 2.0 News and Social Media Coverage News SentimentSavara has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Savara this week, compared to 2 articles on an average week.Search InterestOnly 5 people have searched for SVRA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Savara to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Savara insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.13% of the stock of Savara is held by insiders.Percentage Held by Institutions87.93% of the stock of Savara is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Savara's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Savara are expected to grow in the coming year, from ($0.44) to ($0.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Savara is -11.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Savara is -11.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSavara has a P/B Ratio of 7.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Savara's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About Savara Stock (NASDAQ:SVRA)Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.Read More SVRA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SVRA Stock News HeadlinesSeptember 4 at 10:08 AM | businesswire.comSavara to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 2, 2024 | msn.comSavara, Inc. (SVRA): The Best Multibagger Penny Stock of 2025?September 7, 2024 | Porter & Company (Ad)War on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.September 1, 2024 | americanbankingnews.comSavara Inc (NASDAQ:SVRA) Receives $11.17 Average Price Target from BrokeragesAugust 22, 2024 | msn.comSavara Inc. to Present at European Respiratory Society Congress 2024August 21, 2024 | msn.comSavara Inc. Reports Strong Q2 2024 Results and Positive IMPALA-2 Trial OutcomesAugust 15, 2024 | markets.businessinsider.comEvercore ISI Reaffirms Their Buy Rating on Savara (SVRA)August 13, 2024 | markets.businessinsider.comBuy Rating Affirmed for Savara on Molbreevi’s Commercial Promise and Solid Financial FootingSeptember 7, 2024 | Porter & Company (Ad)War on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.August 13, 2024 | investorplace.comSVRA Stock Earnings: Savara Misses EPS for Q2 2024August 12, 2024 | finance.yahoo.comSavara Reports Second Quarter 2024 Financial Results and Provides Business UpdateJuly 28, 2024 | nasdaq.comSavara Inc. Common Stock (SVRA)June 26, 2024 | seekingalpha.comSavara: Today's Data 'Win' Rouses Market All Too BrieflyJune 26, 2024 | benzinga.comWhy Is Respiratory Disease-Focused Savara Stock Trading Higher On Wednesday?June 26, 2024 | businesswire.comSavara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)June 25, 2024 | businesswire.comSavara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)June 19, 2024 | investorplace.com3 Penny Stocks Poised for Major Upside Over the Next 5 YearsJune 11, 2024 | investorplace.com3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June EditionSee More Headlines Receive SVRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Savara and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/12/2024Today9/07/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SVRA Previous SymbolAMEX:ANX CUSIPN/A CIK1160308 Webwww.savarapharma.com Phone512-614-1848Fax858-552-0876EmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$11.17 High Stock Price Target$16.00 Low Stock Price Target$7.00 Potential Upside/Downside+152.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-54,700,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-58.99% Return on Assets-45.79% Debt Debt-to-Equity Ratio0.26 Current Ratio11.31 Quick Ratio11.31 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.62 per share Price / Book7.13Miscellaneous Outstanding Shares138,189,000Free Float131,100,000Market Cap$610.80 million OptionableOptionable Beta0.97 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesRobert N. Neville (Age 51)Chairman of the Board, Chief Executive Officer Taneli Jouhikainen (Age 51)President, Chief Operating Officer David L. Lowrance (Age 50)Chief Financial Officer Nevan C. Elam (Age 49)Independent Director Richard J. Hawkins (Age 68)Independent Director Joseph S. McCracken Ph.D. (Age 64)Independent Director Matthew Pauls J.D. (Age 46)Independent Director Yuri Pikover (Age 56)Independent Director More ExecutivesKey CompetitorsZevra TherapeuticsNASDAQ:KMPHGreenwich LifeSciencesNASDAQ:GLSISatsuma PharmaceuticalsNASDAQ:STSASynlogicNASDAQ:SYBXPurple BiotechNASDAQ:PPBTView All CompetitorsInsiders & InstitutionsTeachers Retirement System of The State of KentuckyBought 53,403 shares on 8/26/2024Ownership: 0.039%Nantahala Capital Management LLCBought 3,443,541 shares on 8/20/2024Ownership: 3.749%Frazier Life Sciences Management L.P.Bought 4,157,385 shares on 8/16/2024Ownership: 5.903%Algert Global LLCBought 41,377 shares on 8/16/2024Ownership: 0.173%AQR Capital Management LLCSold 4,709 shares on 8/15/2024Ownership: 0.012%View All Insider TransactionsView All Institutional Transactions SVRA Stock Analysis - Frequently Asked Questions How have SVRA shares performed this year? Savara's stock was trading at $4.70 at the beginning of 2024. Since then, SVRA stock has decreased by 6.0% and is now trading at $4.42. View the best growth stocks for 2024 here. How were Savara's earnings last quarter? Savara Inc (NASDAQ:SVRA) issued its quarterly earnings data on Monday, August, 12th. The company reported ($0.12) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by $0.01. Who are Savara's major shareholders? Top institutional investors of Savara include Frazier Life Sciences Management L.P. (5.90%), Nantahala Capital Management LLC (3.75%), Farallon Capital Management LLC (3.30%) and First Light Asset Management LLC (1.45%). Insiders that own company stock include Rick Yang, David A Ramsay, Matthew Pauls, David L Lowrance, Raymond Dennis Pratt, Nevan C Elam and Badrul A Chowdhury. View institutional ownership trends. How do I buy shares of Savara? Shares of SVRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Savara own? Based on aggregate information from My MarketBeat watchlists, some other companies that Savara investors own include BioLineRx (BLRX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Geron (GERN), Inovio Pharmaceuticals (INO) and T2 Biosystems (TTOO). This page (NASDAQ:SVRA) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Savara Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Savara With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
